Phenotypes associated with this allele

• Allele Symbol: Tg(Upk2-cre)6Xrw
• Allele Name: transgene insertion 6, Xue-Ru Wu
• Allele ID: MGI:3583893
• Summary: 15 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Fgfr3^tm4Cxd/Fgfr3^+ Kras^tm4Tyj/Kras^+ Tg(Upk2-cre)6Xrw/0	involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N	MGI:5141739
cn2	Ctnnb1^tm1Mmt/Ctnnb1^tm1Mmt Kras^tm4Tyj/Kras^+ Tg(Upk2-cre)6Xrw/0	involves: 129S4/SvJae * 129X1/SvJ * FVB/N	MGI:5790500
cn3	Ctnnb1^tm1Mmt/Ctnnb1^tm1Mmt Pten^tm1Hwu/Pten^tm1Hwu Tg(Upk2-cre)6Xrw/0	involves: 129S4/SvJae * 129X1/SvJ * FVB/N	MGI:4943268
cn4	Ctnnb1^tm1Mmt/Ctnnb1^+ Pten^tm1Hwu/Pten^tm1Hwu Tg(Upk2-cre)6Xrw/0	involves: 129S4/SvJae * 129X1/SvJ * FVB/N	MGI:4943270
cn5	Ctnnb1^tm1Mmt/Ctnnb1^+ Kras^tm4Tyj/Kras^+ Tg(Upk2-cre)6Xrw/0	involves: 129S4/SvJae * 129X1/SvJ * FVB/N	MGI:5141743
cn6	Kras^tm4Tyj/Kras^+ Tg(Upk2-cre)6Xrw/0	involves: 129S4/SvJae * FVB/N	MGI:5141740
cn7	Kras^tm4Tyj/Kras^+ Pten^tm1Hwu/Pten^+ Tg(Upk2-cre)6Xrw/0	involves: 129S4/SvJae * FVB/N	MGI:5141742
cn8	Ctnnb1^tm1Mmt/Ctnnb1^+ Fgfr3^tm4Cxd/Fgfr3^+ Tg(Upk2-cre)6Xrw/0	involves: 129S6/SvEvTac * 129X1/SvJ * FVB/N	MGI:5141741
cn9	Cdkn1a^tm1Led/Cdkn1a^tm1Led Ctnnb1^tm1Mmt/Ctnnb1^tm1Mmt Tg(Upk2-cre)6Xrw/0	involves: 129S6/SvEvTac * 129X1/SvJ * FVB/N	MGI:5790498
cn10	Fgfr3^tm4Cxd/Fgfr3^+ Tg(Upk2-cre)6Xrw/0	involves: 129S6/SvEvTac * FVB/N	MGI:5141738
cn11	Fgfr3^tm1Iwa/Fgfr3^+ Tg(Upk2-cre)6Xrw/0	involves: 129S6/SvEvTac * FVB/N	MGI:5141737
cn12	Cdkn1a^tm1Led/Cdkn1a^tm1Led Tg(Upk2-cre)6Xrw/0	involves: 129S6/SvEvTac * FVB/N	MGI:5790499
cn13	Ctnnb1^tm1Mmt/Ctnnb1^tm1Mmt Tg(Upk2-cre)6Xrw/0	involves: 129X1/SvJ * FVB/N	MGI:4943263
cn14	Ctnnb1^tm1Mmt/Ctnnb1^+ Tg(Upk2-cre)6Xrw/0	involves: 129X1/SvJ * FVB/N	MGI:4943264
cn15	Ctnnb1^tm1Mmt/Ctnnb1^tm1Mmt Tg(Upk2-cre)6Xrw/0 Tg(Upk2-HRAS*Q61L)5Xrw/0	involves: 129X1/SvJ * FVB/N	MGI:5790497

Genotype
MGI:5141739

cn1

• Allelic Composition: Fgfr3^tm4Cxd/Fgfr3⁺; Kras^tm4Tyj/Kras⁺; Tg(Upk2-cre)6Xrw/0
• Genetic Background: involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

integument

increased skin papilloma incidence ( J:174242 )

• by 1 year of age, 44% of mutants develop skin papilloma, with tumors reaching 1 cm in diameter by a median of 220 days

mortality/aging

premature death ( J:174242 )

• shorter survival due to skin papillomas, with a survival time between 100-400 days

neoplasm

neoplasm ( J:174242 )

N • mice aged to 12 month do not develop urothelial hyperplasia or urothelial carcinoma or lung tumors

increased skin papilloma incidence ( J:174242 )

• by 1 year of age, 44% of mutants develop skin papilloma, with tumors reaching 1 cm in diameter by a median of 220 days

Genotype
MGI:5790500

cn2

• Allelic Composition: Ctnnb1^tm1Mmt/Ctnnb1^tm1Mmt; Kras^tm4Tyj/Kras⁺; Tg(Upk2-cre)6Xrw/0
• Genetic Background: involves: 129S4/SvJae * 129X1/SvJ * FVB/N

mortality/aging

premature death ( J:234236 )

• mean survival of 185 days and median survival of 200 days

neoplasm

increased urinary bladder carcinoma incidence ( J:234236 )

• mice rapidly develop bladder tumors resembling urothelial cell carcinoma

renal/urinary system

increased urinary bladder carcinoma incidence ( J:234236 )

• mice rapidly develop bladder tumors resembling urothelial cell carcinoma

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
urinary bladder cancer		DOID:11054	OMIM:109800	J:234236

Genotype
MGI:4943268

cn3

• Allelic Composition: Ctnnb1^tm1Mmt/Ctnnb1^tm1Mmt; Pten^tm1Hwu/Pten^tm1Hwu; Tg(Upk2-cre)6Xrw/0
• Genetic Background: involves: 129S4/SvJae * 129X1/SvJ * FVB/N

mortality/aging

premature death ( J:164579 )

neoplasm

increased urinary bladder carcinoma incidence ( J:164579 )

• mice develop urothelial bladder tumors that progress to papillary carcinoma

renal/urinary system

increased urinary bladder carcinoma incidence ( J:164579 )

• mice develop urothelial bladder tumors that progress to papillary carcinoma

Genotype
MGI:4943270

cn4

• Allelic Composition: Ctnnb1^tm1Mmt/Ctnnb1⁺; Pten^tm1Hwu/Pten^tm1Hwu; Tg(Upk2-cre)6Xrw/0
• Genetic Background: involves: 129S4/SvJae * 129X1/SvJ * FVB/N

mortality/aging

premature death ( J:164579 )

neoplasm

increased urinary bladder carcinoma incidence ( J:164579 )

• mice develop urothelial bladder tumors that progress to papillary carcinoma

renal/urinary system

increased urinary bladder carcinoma incidence ( J:164579 )

• mice develop urothelial bladder tumors that progress to papillary carcinoma

Genotype
MGI:5141743

cn5

• Allelic Composition: Ctnnb1^tm1Mmt/Ctnnb1⁺; Kras^tm4Tyj/Kras⁺; Tg(Upk2-cre)6Xrw/0
• Genetic Background: involves: 129S4/SvJae * 129X1/SvJ * FVB/N

neoplasm

increased lung tumor incidence ( J:174242 )

respiratory system

increased lung tumor incidence ( J:174242 )

Genotype
MGI:5141740

cn6

• Allelic Composition: Kras^tm4Tyj/Kras⁺; Tg(Upk2-cre)6Xrw/0
• Genetic Background: involves: 129S4/SvJae * FVB/N

neoplasm

neoplasm ( J:174242 , J:234236 )

N • mutants aged up to 18 months do not develop skin papillomas, bladder tumors or lung tumors (J:174242)

N (J:234236)

renal/urinary system

renal/urinary system phenotype ( J:234236 )

N • mice do not develop urothelium hyperplasia or bladder tumors

Genotype
MGI:5141742

cn7

• Allelic Composition: Kras^tm4Tyj/Kras⁺; Pten^tm1Hwu/Pten⁺; Tg(Upk2-cre)6Xrw/0
• Genetic Background: involves: 129S4/SvJae * FVB/N

integument

increased skin papilloma incidence ( J:174242 )

• 42% of mutants develop skin papillomas

neoplasm

increased skin papilloma incidence ( J:174242 )

• 42% of mutants develop skin papillomas

Genotype
MGI:5141741

cn8

• Allelic Composition: Ctnnb1^tm1Mmt/Ctnnb1⁺; Fgfr3^tm4Cxd/Fgfr3⁺; Tg(Upk2-cre)6Xrw/0
• Genetic Background: involves: 129S6/SvEvTac * 129X1/SvJ * FVB/N

mortality/aging

premature death ( J:174242 )

• shorter survival due to lung cancer, with a survival time between 200-400 days

renal/urinary system

abnormal urinary bladder urothelium morphology ( J:174242 )

• 100% of mutants exhibit areas of hyperproliferation in the bladder urothelium from about 3 months of age, however these lesions do not progress further when examined at 12 months of age

neoplasm

neoplasm ( J:174242 )

N • despite hyperproliferation in the bladder, mutants do not develop urothelial carcinoma by 12 months of age

N • mutants do not develop skin papillomas

increased lung tumor incidence ( J:174242 )

• 36% of mutants develop lung tumors by 1 year of age

• lung tumors resemble solitary fibrous tumors of the lugs (hemangiopericytomas)

respiratory system

increased lung tumor incidence ( J:174242 )

• 36% of mutants develop lung tumors by 1 year of age

• lung tumors resemble solitary fibrous tumors of the lugs (hemangiopericytomas)

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
lung cancer		DOID:1324	OMIM:211980 OMIM:608935 OMIM:612571 OMIM:612593 OMIM:614210	J:174242

Genotype
MGI:5790498

cn9

• Allelic Composition: Cdkn1a^tm1Led/Cdkn1a^tm1Led; Ctnnb1^tm1Mmt/Ctnnb1^tm1Mmt; Tg(Upk2-cre)6Xrw/0
• Genetic Background: involves: 129S6/SvEvTac * 129X1/SvJ * FVB/N

mortality/aging

premature death ( J:234236 )

• mean survival of 237 days and median survival of 238 days

neoplasm

increased urinary bladder carcinoma incidence ( J:234236 )

• mice rapidly develop urothelial cell carcinoma

renal/urinary system

increased urinary bladder carcinoma incidence ( J:234236 )

• mice rapidly develop urothelial cell carcinoma

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
urinary bladder cancer		DOID:11054	OMIM:109800	J:234236

Genotype
MGI:5141738

cn10

• Allelic Composition: Fgfr3^tm4Cxd/Fgfr3⁺; Tg(Upk2-cre)6Xrw/0
• Genetic Background: involves: 129S6/SvEvTac * FVB/N

neoplasm

neoplasm ( J:174242 )

N • mutants do not develop skin or lung tumors, or urothelial hyperplasia, dysplasia or carcinoma

Genotype
MGI:5141737

cn11

• Allelic Composition: Fgfr3^tm1Iwa/Fgfr3⁺; Tg(Upk2-cre)6Xrw/0
• Genetic Background: involves: 129S6/SvEvTac * FVB/N

neoplasm

neoplasm ( J:174242 )

N • mutants do not develop skin or lung tumors, or urothelial hyperplasia, dysplasia or carcinoma

Genotype
MGI:5790499

cn12

• Allelic Composition: Cdkn1a^tm1Led/Cdkn1a^tm1Led; Tg(Upk2-cre)6Xrw/0
• Genetic Background: involves: 129S6/SvEvTac * FVB/N

neoplasm

neoplasm ( J:234236 )

N • mice do not develop urothelial tumors or other urothelial abnormalities

Genotype
MGI:4943263

cn13

• Allelic Composition: Ctnnb1^tm1Mmt/Ctnnb1^tm1Mmt; Tg(Upk2-cre)6Xrw/0
• Genetic Background: involves: 129X1/SvJ * FVB/N

renal/urinary system

abnormal urinary bladder urothelium morphology ( J:164579 , J:234236 )

• mice develop hyperplastic lesions in the bladder unlike wild-type mice (J:164579)

• mice develop premalignant bladder lesions (J:234236)

neoplasm

neoplasm ( J:164579 )

N • hyperproliferative lesions in the bladder do not progress to carcinoma

Genotype
MGI:4943264

cn14

• Allelic Composition: Ctnnb1^tm1Mmt/Ctnnb1⁺; Tg(Upk2-cre)6Xrw/0
• Genetic Background: involves: 129X1/SvJ * FVB/N

renal/urinary system

abnormal urinary bladder urothelium morphology ( J:164579 , J:174242 )

• mice develop hyperplastic lesions in the bladder unlike wild-type mice (J:164579)

• 100% of mutants exhibit areas of hyperproliferation in the bladder urothelium from about 3 months of age, however these lesions do not progress further when examined at 12 months of age (J:174242)

neoplasm

neoplasm ( J:164579 , J:174242 )

N • hyperproliferative lesions in the bladder do not progress to carcinoma (J:164579)

N • mutants aged up to 18 months do not develop lung tumors, skin tumors or urothelial carcinoma (J:174242)

Genotype
MGI:5790497

cn15

• Allelic Composition: Ctnnb1^tm1Mmt/Ctnnb1^tm1Mmt; Tg(Upk2-cre)6Xrw/0; Tg(Upk2-HRAS*Q61L)5Xrw/0
• Genetic Background: involves: 129X1/SvJ * FVB/N

mortality/aging

premature death ( J:234236 )

• mean survival of 231 days and median survival of 236 days

neoplasm

increased urinary bladder carcinoma incidence ( J:234236 )

• mice rapidly develop bladder tumors with progression to non-invasive papillary carcinomas (urothelial cell carcinoma)

• the number of proliferating cells within each tumor is increased compared to single conditional Ctnnb1^tm1Mmt homozygotes

• mice treated with a MEK1/2 inhibitor, PD184352, show tumor regression and reduction in proliferation

renal/urinary system

hematuria ( J:234236 )

• due to bladder tumors

increased urinary bladder carcinoma incidence ( J:234236 )

• mice rapidly develop bladder tumors with progression to non-invasive papillary carcinomas (urothelial cell carcinoma)

• the number of proliferating cells within each tumor is increased compared to single conditional Ctnnb1^tm1Mmt homozygotes

• mice treated with a MEK1/2 inhibitor, PD184352, show tumor regression and reduction in proliferation

homeostasis/metabolism

hematuria ( J:234236 )

• due to bladder tumors

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
urinary bladder cancer		DOID:11054	OMIM:109800	J:234236